Products
Research Areas
COVID-19
Resources
Contact Us
Distributors
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us
LSBio
2401 Fourth Avenue Suite 900
Seattle WA 98121
Phone:
866-819-4732 (Toll Free North America
206-374-1102 (International)
Fax:
866-206-6909 (Toll Free North America)
206-577-4565 (International)
How To Buy - Details about how to buy our products.
Orders@LSBio.com - To submit a new order.
Customer.Support@LSBio.com - To submit questions about existing orders, pricing, availability, bulk quotes, Proforma invoice requests, or other billing issues.
Technical.Support@LSBio.com - To request technical information about an LSBio product or its applications
Sales@LSBio.com - To request information about distribution agreements, or general business development.
Worldwide Distributors List - To find your local distributor if you're not within the United States.
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-G3752-10 10 µg $292 
LS-G3752-50 50 µg $474 
IL-33 Protein - Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.
IL-33 Protein - Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
IL-33 Protein - Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.
IL-33 Protein - Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
1 of 2
2 of 2

Human IL-33 Protein (Recombinant His) (aa112-270) - LS-G3752

Human IL-33 Protein (Recombinant His) (aa112-270) - LS-G3752

Description:
IL-33 Protein LS-G3752 is a Recombinant Human IL-33 produced in E. coli aa 112-270 with His tag(s). It is low in endotoxin; Less than 1.0 EU/µg protein (determined by LAL method).
Price
Catalog Number
$292
LS-G3752-10
Toll Free North America
866-819-4732
For Research Use Only

Overview

Description:
IL-33 Protein LS-G3752 is a Recombinant Human IL-33 produced in E. coli aa 112-270 with His tag(s). It is low in endotoxin; Less than 1.0 EU/µg protein (determined by LAL method).

Specifications

Type
Recombinant Protein
Target
IL-33
Synonyms
IL33 | C9orf26 | DVS27 | DVS27-related protein | IL-1F11 | IL-33 | Interleukin-33 | NFEHEV | NF-HEV | Interleukin-1 family member 11 | NFHEV | IL1F11 | Interleukin 33 | RP11-575C20.2
Species
Human
Modifications
Unmodified
Conjugations
Unconjugated
Tag
His
Region
aa 112-270
Predicted Molecular Weight
~18kDa (SDS-PAGE)
Expression System
E. coli
Source Species
E. coli
Purification
Greater than 90% by SDS-PAGE
Bio-Activity
Activates human ST2-dependent NF-kappaB pathway.
Endotoxin
Less than 1.0 EU/µg protein (determined by LAL method).
Presentation
55 mM Tris-HCl, pH 8.2, 150 mM NaCl
Storage
Store at 4°C for immediate use, or aliquot and store at -20°C for up to 3 months. Avoid freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This protein carries the LSBio 100% Guarantee.
LSBio Guarantee
About IL-33
O95760 NM_033439 NP_254274.1

Publications (0)

Customer Reviews (0)

Images

Functional Assay

IL-33 Protein - Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.
Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.

Functional Assay

IL-33 Protein - Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.

Functional Assay

IL-33 Protein - Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.
Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.

Functional Assay

IL-33 Protein - Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.

Functional Assay

IL-33 Protein - Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.
Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.

Functional Assay

IL-33 Protein - Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.

Functional Assay

IL-33 Protein - Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.
Activation of a human ST2-dependent NF-kappaB pathway. HEK-293 cells were transiently co-transfected with 500 ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-kappaB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in a 12-well plate. 40 hours after transfection, cells were treated with IL33 (human) (rec.) (His) at the concentration as indicated for 8 hours, followed by measurement with a dual luciferase assay.

Functional Assay

IL-33 Protein - Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.
Pull down assay: a) pull down of hIL-33-His by hST2-Fc b) pull down of hST2-Fc by hIL-33-His 5 ug of hST2-Fc (or control Fc protein), 2 ug of hIL-33-His (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4 degrees C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of hIL-33-His or hST2-Fc with anti-His HRP or anti-hIgG HRP, respectively.

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 6/20/2021